Who Paid My Doc
Stephen Morris
Neuroradiology Memphis, TN Medical Doctor
NPI 1508971995 CMS profile 520315
6325 Humphreys Blvd, Semmes Murphey Clinic, Memphis, TN 38120
General payments
$56,350
Research payments
$36,868
Ownership & investment interest
$0
Through program year 2025, Stephen Morris of Memphis, TN is reported in the CMS Open Payments database as having received $56,350 across 11 general payments and $36,868 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 94th percentile of Neuroradiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $30,867 | 3 | |
| 2024 | General | $25,093 | 2 | |
| 2023 | General | $17 | 1 | |
| 2022 | Research | $24,800 | 3 | |
| 2021 | Research | $4,037 | 1 | |
| 2020 | Research | $8,031 | 1 | |
| 2019 | General | $373 | 5 |
Beside peers
- Stephen Morris
- Neuroradiology median
- Middle half of Neuroradiology
- National median
In program year 2025, general payments to Stephen Morris were reported at $30,867. Among 399 Neuroradiology profiles paid that year, the median was $279 and the middle half received between $65 and $2,205.
Show as a table
| Year | Stephen Morris | Neuroradiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $373 | $288 | $71–$2,035 | $163 |
| 2020 | $0 | $165 | $32–$1,794 | $114 |
| 2021 | $0 | $238 | $42–$1,807 | $132 |
| 2022 | $0 | $191 | $49–$1,388 | $149 |
| 2023 | $17 | $228 | $56–$1,148 | $160 |
| 2024 | $25,093 | $241 | $97–$2,192 | $164 |
| 2025 | $30,867 | $279 | $65–$2,205 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 63 billing codesPaid by Medicare
$136,747
Medicare patients
1,722
Services billed
4,427
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 64% | |
| Ischemic heart disease | 44% | |
| Diabetes | 37% | |
| Chronic kidney disease | 32% | |
| Depression | 31% | |
| Heart failure | 26% | |
| Atrial fibrillation | 26% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, gadobutrol, 0.1 ml A9585 | Office | 13 | 1,280 | $323 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
16 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neuroradiology in Tennessee
Related records
Neuroradiology in Tennessee
Practitioners in the same specialty and state, ranked by reported value.
All Neuroradiology
Everyone recorded under this specialty, nationwide.
Doctors in Tennessee
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.